Speed dating kennewick wa
/PRNewswire/ – Stealth Bio Therapeutics (Stealth), a clinical-stage biopharmaceutical company developing therapeutics to treat mitochondrial dysfunction, today announced that the U. Food and Drug Administration (FDA) Office of Orphan Products Development has granted Orphan Drug Designation to Stealth’s investigational drug candidate, elamipretide, for the treatment of patients with Barth syndrome.” There are currently no FDA-approved therapies for patients with Barth syndrome, a debilitating condition characterized by heart and skeletal muscle weakness,” said , Stealth’s chief executive officer.Discussions with the FDA started in early 2017, says Cognoa CEO Brent Vaughan, adding that it’s hoping to gain full FDA clearance this year.He says the ultimate goal for the US startup is to become a standard part of domestic health insurance-covered medical provision — and for that FDA clearance is essential to opening the doors.“We believe elamipretide represents a promising, novel approach with the potential to offer hope for patients with Barth syndrome, and we are very pleased to have received Orphan Drug Designation for this indication.” , Stealth announced the completion of enrollment in the TAZPOWER clinical trial, a phase 2/3 crossover study evaluating the effects of daily treatment with elamipretide in 12 patients with genetically confirmed Barth syndrome followed by an open-label treatment extension.
This results in a logjam of children, with varying levels of severity, waiting for these assessments,” Dr.“We were lucky that we had investors,” says Vaughan.“There’s not a huge business model in providing free screening services to kids, right, because we were certainly never going to sell ads. To view the full document, please visit https://techcrunch.com/2018/02/21/cognoas-ai-platform-for-autism-diagnosis-gets-first-fda-stamp Palo Alto, California-based Cognoa’s machine learning app for pediatric behavioral health has received categorization from the FDA as a Class 2 diagnostic medical device for autism, according to an announcement from the company.Secondary endpoints include additional functional assessments, patient-reported outcomes and safety.
Data from the TAZPOWER trial are expected later this year.Speaking to Tech Crunch, Vaughn said that his company will likely raise another round of investments by the end of the year. 15, 2017 (GLOBE NEWSWIRE) — Nu Cana plc (NASDAQ: NCNA) announced the enrollment of the first patients in both the United States and the United Kingdom in its PRO-105 study evaluating single-agent Acelarin (NUC-1031) in patients with platinum-resistant ovarian cancer.Hugh Griffith, Nu Cana’s Chief Executive Officer, stated: “The initiation of this Phase 2 study of Acelarin in both the US and the UK is a major step in the expansion of the Nu Cana product pipeline and advances our strategy of rapidly developing our Pro Tides to benefit cancer patients globally.The primary endpoint of the study will be Objective Response Rate, and secondary endpoints include Duration of Response, Progression-Free Survival, Overall Survival and safety parameters.